BioAnalytics Pro is a Cambridge-based biotechnology company that has secured $45 million in Series A funding. The company operates in the biotech sector, likely developing advanced analytics or data processing solutions for life sciences applications, as suggested by its name.
Being based in Cambridge positions the company within one of the world's leading biotech ecosystems, providing access to top-tier research institutions like MIT and Harvard, as well as a deep talent pool. The substantial Series A funding round indicates strong early market validation and investor confidence in the company's technology and business model, though specific product offerings and target markets remain undisclosed.
| Date | Round | Amount | Lead Investor |
|---|---|---|---|
| Jan 2026 | Series A | $45M | Lux Capital |
Cambridge-based biotech company developing advanced analytics solutions for life sciences applications.
BioAnalytics Pro has raised $45M in total funding, with their most recent round being a Series A. The company operates in the Biotech sector.
BioAnalytics Pro operates in the Biotech sector. Cambridge-based biotech company developing advanced analytics solutions for life sciences applications.
